Ibrutinib (also translated as Yilutini; brand name: Yike; Incepta).

Product introduction:
Ibrutinib (also translated as Yilutini; generic name: Ibrutinib; brand names: Imbruvica, Yike), produced by Incepta, is an oral Bruton’s tyrosine kinase (BTK) inhibitor. It exerts its antitumor effect by inhibiting BTK, which is essential for tumor cell proliferation and metastasis.

It is used for the treatment of relapsed mantle cell lymphoma (MCL), relapsed chronic lymphocytic leukemia (CLL), CLL with 17p deletion, and Waldenström’s macroglobulinemia.

Ibrutinib is also being developed for additional therapeutic areas beyond its approved indications, with more than 10 diseases under investigation, including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), and acute lymphoblastic leukemia (ALL).

In addition to hematologic malignancies, Ibrutinib is also being explored for autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, as well as other rare conditions including graft-versus-host disease (GVHD).

Brand introduction:
Incepta Pharmaceuticals is the second-largest pharmaceutical company in Bangladesh, founded in 1999. The company currently operates a portfolio of 783 products, exports to 59 countries, and continues to expand globally. Incepta Pharmaceuticals has obtained GMP certifications from countries including the United Kingdom, Germany, and Canada.

Indications:
Ibrutinib is indicated for the treatment of:
(1) Patients with mantle cell lymphoma (MCL) who have received at least one prior therapy;
(2) Patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

These indications are based on overall response rate; improvement in survival or disease-related symptoms has not been established.

Dosage and administration:
MCL: 560 mg orally once daily (four 140 mg capsules once daily).
CLL: 420 mg orally once daily (three 140 mg capsules once daily).

Capsules should be taken orally with a glass of water. Do not open or chew the capsules.